user

A phase II study of Halichondrin B analog eribulin mesylate (E7389) as second-line therapy for patients with advanced pancreatic cancer

被引：0
|
作者：
Moore, M. J.
Tang, P.
Renouf, D.
Major, P.
Hedley, D.
Paterson, V.
Wang, L.
Dhesy-Thind, B.
Southwood, B.
Doyle, L.
机构：
[1] Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada
[2] Tom Baker Canc Clin, Calgary, AB, Canada
[3] Juravinski Canc Ctr, Hamilton, ON, Canada
[4] CTEP, Washington, DC USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2009年 / 27卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e15634
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Phase II study of eribulin mesylate (E7389) halichondrin b analog in patients with refractory breast cancer
    Blum, J. L.
    Pruitt, B.
    Fabian, C. J.
    Rivera, R. R.
    Shuster, D. E.
    Meneses, N. L.
    Chandrawansa, K.
    Fang, F.
    Fields, S. Z.
    Vahdat, L.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [2] Eribulin mesylate (halichondrin B analog E7389) in platinum-sensitive ovarian cancer: A phase II study, CTEP #7431.
    Hensley, M. L.
    Kravetz, S. J.
    Jia, X.
    Tew, W. P.
    Pereira, L.
    Sabbatini, P.
    Whalen, C.
    Aghajanian, C.
    Zarwan, C.
    Berlin, S. T.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [3] A phase II study of the halichondrin B analog eribulin mesylate in gemcitabine refractory advanced pancreatic cancer
    Renouf, Daniel J.
    Tang, Patricia A.
    Major, Pierre
    Krzyzanowska, Monika K.
    Dhesy-Thind, Bindi
    Goffin, John R.
    Hedley, David
    Wang, Lisa
    Doyle, L.
    Moore, Malcolm J.
    [J]. INVESTIGATIONAL NEW DRUGS, 2012, 30 (03) : 1203 - 1207
  • [4] A phase II study of the halichondrin B analog eribulin mesylate in gemcitabine refractory advanced pancreatic cancer
    Daniel J. Renouf
    Patricia A. Tang
    Pierre Major
    Monika K. Krzyzanowska
    Bindi Dhesy-Thind
    John R. Goffin
    David Hedley
    Lisa Wang
    L. Doyle
    Malcolm J. Moore
    [J]. Investigational New Drugs, 2012, 30 : 1203 - 1207
  • [5] A Phase II Study of Halichondrin B Analog Eribulin Mesylate (E7389) in Patients with Advanced Non-small Cell Lung Cancer Previously Treated with a Taxane A California Cancer Consortium Trial
    Gitlitz, Barbara J.
    Tsao-Wei, Denice D.
    Groshen, Susan
    Davies, Angela
    Koczywas, Marianna
    Belani, Chandra P.
    Argiris, Athanassios
    Ramalingam, Suresh
    Vokes, Everett E.
    Edelman, Martin
    Hoffman, Philip
    Ballas, Marc S.
    Liu, Stephen V.
    Gandara, David R.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (03) : 574 - 578
  • [6] Eribulin mesylate (halichondrin B Analog E7389) in platinum-resistant epithelial ovarian cancer (PR-EOC): A CTEP-sponsored phase II study
    Hensley, M. L.
    Kravetz, S.
    Sima, C.
    Tew, W.
    Pereira, L.
    Sabbatini, P.
    Whalen, C.
    Aghajanian, C. A.
    Zarwan, C.
    Berlin, S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [7] Antiproliferative effects of halichondrin B analog eribulin mesylate (E7389) against paclitaxel-resistant human cancer cells in vitro
    Kuznetsov, Galina
    TenDyke, Karen
    Yu, Melvin J.
    Littlefield, Bruce A.
    [J]. MOLECULAR CANCER THERAPEUTICS, 2007, 6 (12) : 3545S - 3545S
  • [8] A phase I study of eribulin mesylate (E7389) in patients with refractory cancers
    Minami, H.
    Mukohara, T.
    Nagai, S.
    Mukai, H.
    Namiki, M.
    [J]. EJC SUPPLEMENTS, 2008, 6 (12): : 140 - 140
  • [9] Eribulin mesylate (halichondrin B analog E7389) in platinum-resistant and platinum-sensitive ovarian cancer A 2-Cohort, Phase 2 Study
    Hensley, Martee L.
    Kravetz, Sara
    Jia, Xiaoyu
    Iasonos, Alexia
    Tew, William
    Pereira, Lauren
    Sabbatini, Paul
    Whalen, Christin
    Aghajanian, Carol A.
    Zarwan, Corinne
    Berlin, Suzanne
    [J]. CANCER, 2012, 118 (09) : 2403 - 2410
  • [10] A Phase II Study of Eribulin Mesylate (E7389) in Patients With Advanced, Previously Treated Non-Small-Cell Lung Cancer
    Spira, Alexander I.
    Iannotti, Nicholas O.
    Savin, Michael A.
    Neubauer, Marcus
    Gabrail, Nashat Y.
    Yanagihara, Ronald H.
    Zang, Edith A.
    Cole, Patricia E.
    Shuster, Dale
    Das, Asha
    [J]. CLINICAL LUNG CANCER, 2012, 13 (01) : 31 - 38
12345